Biovian is clearing bottlenecks in gene therapy production with its complete one-stop-shop service. Guided by its Nordic ethos, the contract development and manufacturing organization (CDMO) has built ...

The CDMOs are joining together to offer end-to-end development and manufacturing services for protein expression systems and viral vectors in Europe. Biovian, a contract development and manufacturing ...

Biovian, a CDMO, invested over €50M to expand its manufacturing facility in Turku, Finland. The new facility will have an area of 6,400 m 2 (69,000 ft 2) and advanced equipment and technologies to ...

ERES IV, advised by Elyan Partners, and Sodena, to remain minority shareholders Dámaso Molero Sánchez, former 3P CEO, will serve as group CEO Keensight is a European growth buyout firm Biovian and 3P ...

Biovian, a Finland-based CDMO, earmarked 50 million euros ($55 million) to expand its advanced therapy manufacturing operations in Turku, Finland. The project will feature a new 69,000-square-foot ...

Biovian and 3P Biopharmaceuticals combined companies to create a new pan-European independent CDMO named 3PBIOVIAN. A spokesperson says the new group will offer end-to-end development and ...

The expansion project is aimed to be completed in December 2024 and the new facility will be fully operational by 2025. Biovian Oy announced a major investment of over €50 million to expand its ...

STOCKHOLM, Dec. 31, 2020 /PRNewswire/ -- Eurocine Vaccines AB ("Eurocine Vaccines" or the "Company") has today selected Biovian Oy, Turku, Finland, ("Biovian") as the contract developer for the ...

STOCKHOLM, June 1, 2018 /PRNewswire/ -- EQT Credit, through its Mid-Market investment strategy, is pleased to announce that it has provided the financing to support Keensight Capital and ERES' (the ...

Lokon Pharma’s immunostimulatory gene therapy, delivered in oncolytic adenoviruses, are poised to enter pivotal trials for cancer. Biovian Oy is manufacturing Lokon’s immunotherapeutics for these ...